Rizatriptan

DEA Class; Rx

Common Brand Names; Maxalt, Maxalt MLT

• Serotonin 5-HT-Receptor Agonists; 
• Antimigraine Agents

Hypersensitivity

Ischemic heart disease, uncontrolled hypertension, or other significant cardiovascular disease

Coronary artery vasospasm

History of stroke or transient ischemic attack

Ischemic bowel

Peripheral vascular disease

Basilar or hemiplegic migraine

Within 24 hours of another 5-HT1 agonist or ergot derivative

Within 2 weeks of MAOI

• Drowsiness (13-30%, dose related)
• Fatigue (13-30%, dose related)
• Dizziness (11-15%)
• Dizziness (4-9%)
• Somnolence (4-8%)
• Fatigue (4-7%; dose related)
• Nausea (4-6%)
• Asthenia (1-5%)
• Hot flashes (1-5%)
• Paresthesia (3-4%)
• Dry mouth (3%)
• Chest pain (2-3%)
• Pain/pressure in chest, neck, throat, jaw (<2%)
• Headache (<2%)
• Dyspnea (>1%)
• Hypoesthesia (>1%)
• Palpations (>1%)
• Skin flushing (>1%)

Use caution in hepatic/renal insufficiency

Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache)

Coronary artery vasospasm, ventricular tachycardia/fibrillation, cardiac arrest, myocardial infarction, transient ischemia, and death reported with the use of 5-HT1 agonists

Cerebral/subarachnoid hemorrhage and stroke reported with the use of 5-HT1 agonists

Significant hypertension or hypertensive crisis reported in patients with and without history of hypertension

Not for use in the prevention of migraine or the treatment of cluster headaches

Maxalt-MLT tablets contain phenylalanine (not for use in patients with phenylketonuria)

Patients with sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal’s angina before administering additional doses; monitor with ECG if dosing is resumed and similar symptoms occur

Peripheral vascular ischemia and colonic ischemia, gastrointestinal ischemia/infarction, splenic infarction, and Raynaud’s syndrome reported with 5-HT1 agonist

Transient or permanent partial vision loss and blindness reported (rare)

Available data in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage

Data are not available on the presence of rizatriptan or any active metabolites in human milk, or on the effects of rizatriptan on the breastfed infant, or on milk production

Rizatriptan

tablet

• 5mg
• 10mg

tablet, oral disintegrating

• 5mg
• 10mg